SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A PHASE 3 TRIAL WITH SUBCUTANEOUS LOADING AND MAINTENANCE DOSING (MEASURE 2)

Category Primary study
JournalRheumatology
Year 2017
This article has no abstract
Epistemonikos ID: 427be138d0f30e5e07287c5dd35ecf6ec1e46fef
First added on: Mar 15, 2025